HeraMED Ltd. (AU:HMD)
ASX:HMD
Want to see AU:HMD full AI Analyst Report?
HMD Stock Chart & Stats
AU$0.04
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.04
AU$0.00(0.00%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.06
Previous CloseN/A
Volume370.09K
Average Volume (3M)1.96M
Market Cap
AU$56.59M
Enterprise ValueAU$27.09M
Total Cash (Recent Filing)AU$914.65K
Total Debt (Recent Filing)AU$282.39K
Price to Earnings (P/E)―
Beta1.89
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,154,986,600
10 Day Avg. Volume1,195,844
30 Day Avg. Volume1,958,766
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)27.61
Price to Sales (P/S)131.32
P/FCF Ratio-10.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Gross Margin ImprovementA sustained gross margin near 60% implies strong unit economics for HeraMED’s software and connected-care offerings. Durable high gross margins create potential to fund product R&D and scale customer support as revenue grows, improving prospects for future operating leverage.
Deleveraged Balance SheetZero reported debt reduces financial distress risk and lowers fixed financing obligations, giving management flexibility in capital allocation and partnership negotiations. This structural de-leveraging improves resilience while the company seeks profitable scale.
Focused Digital Women’s Health PlatformA specialized platform targeting maternal care and pregnancy monitoring aligns with secular trends toward remote care and telehealth. Focused domain expertise and data capture can create durable competitive advantages through clinical workflows, regulatory familiarity and sticky provider integrations.
Bears Say
Persistent LossesSustained operating and net losses erode equity and limit the firm’s ability to self-fund growth or absorb setbacks. Over months, continuing losses increase reliance on external capital, which can dilute shareholders or constrain strategic investments needed to reach durable profitability.
Negative Operating Cash FlowOngoing negative operating and free cash flow indicate the business consumes cash to operate. This persistent cash burn heightens liquidity and refinancing risk, limiting runway for sales expansion or product investment absent fresh funding or a clear path to sustained positive cash generation.
Revenue Volatility & Recent ContractionInconsistent top-line growth and recent year-on-year declines undermine the company’s ability to scale fixed-cost investments and achieve operating leverage. Structural revenue volatility complicates forecasting, weakens bargaining power with partners, and lengthens the timeline to durable profitability.
HeraMED Ltd. News
HMD FAQ
What was HeraMED Ltd.’s price range in the past 12 months?
HeraMED Ltd. lowest share price was <AU$0.01 and its highest was AU$0.06 in the past 12 months.
What is HeraMED Ltd.’s market cap?
HeraMED Ltd.’s market cap is AU$56.59M.
When is HeraMED Ltd.’s upcoming earnings report date?
HeraMED Ltd.’s upcoming earnings report date is Sep 01, 2026 which is in 129 days.
How were HeraMED Ltd.’s earnings last quarter?
HeraMED Ltd. released its earnings results on Feb 26, 2026. The company reported -AU$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.002.
Is HeraMED Ltd. overvalued?
According to Wall Street analysts HeraMED Ltd.’s price is currently Overvalued.
Does HeraMED Ltd. pay dividends?
HeraMED Ltd. does not currently pay dividends.
What is HeraMED Ltd.’s EPS estimate?
HeraMED Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does HeraMED Ltd. have?
HeraMED Ltd. has 1,154,986,600 shares outstanding.
What happened to HeraMED Ltd.’s price movement after its last earnings report?
HeraMED Ltd. reported an EPS of -AU$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.556%.
Which hedge fund is a major shareholder of HeraMED Ltd.?
Currently, no hedge funds are holding shares in AU:HMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
HeraMED Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:HMD Sentiment 62%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth AU$57.5K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
―
20 days / 200 days
Momentum
100.00%
12-Months-Change
Fundamentals
Return on Equity
-417.72%
Trailing 12-Months
Asset Growth
-68.43%
Trailing 12-Months
Company Description
HeraMED Ltd.
HeraMED Limited, together with its subsidiaries, develops, manufactures, and sells foetal heart beat monitors and other pregnancy monitoring solutions for home use in Australia, Europe, and Israel. The company provides HeraBEAT, a fetal heart rate monitor use by an expectant mother to monitor their fetus' heartbeat; and HeraCARE, a digital pregnancy monitor platform for the creation and implementation of digital health solutions for maternity care management. It also develops EchoBEAT, the next generation of its home-oriented pregnancy monitoring devices; and Orion, an artificial intelligence powered pregnancy monitoring system for pregnancy monitoring analysis. The company has a collaboration agreement with Mayo Clinic for the development of its HeraCARE pregnancy management platform. HeraMED Limited was incorporated in 2011 and is headquartered in Netanya, Israel.